LABT · Lakewood-Amedex Biotherapeutics Inc.
$1.94
-0.16 (-7.62%)
At close · Jul 29
Going-concern doubt
— flagged May 22, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, substantial doubt regarding the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued has not been alleviated.”View the 10-Q filed May 22, 2026
Market Cap
$13.52M
Shares
7.00M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.10
Open$2.26
Day$1.93–2.50
52W$1.66–98.20
Avg vol 30d3.0M
Short int24K · 0.3% float · 1.0d
Short vol33%
DataApr 2026–Jul 2026
Filing10-Q · May 22
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 22, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Limited
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
−58%
below
RSI (14)
28
oversold
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.34% of float · ▼ -36.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Squeeze score
35
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
265%
annualized · 1-yr
Max drawdown
−98%
past year
ATR
52.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
−58%
Bearish
RSI (14)
28
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.34% of float · ▼ -36.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
52-wk low $2
Now $2 · 0%
52-wk high $98
vs 50-day avg -58%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LABT
this stock
Lakewood-Amedex Biotherapeutics Inc.
|
$13.52M | — | — | — | 0.3% |
|
ONC
BeOne Medicines Ltd.
|
$474.96B | +8.8% | +22179.2% | 966.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LABT | +12.9% | -39.7% | — | -33.1% | — |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | +13.9% | -39.6% | — | -32.3% | — |